Compound I (Fig. 1) exhibited the highest EGFR and HER-2 inhibitory activity (IC50 = 0.09 μM for EGFR and IC50 = 0.42 μM for HER-2) in breast cancer (MCF-7) cancer cell lines relative to erlotinib. Here, ERBB2 is linked to breast cancer.